Posts

Epidemiology, pathogenesis and therapeutic management of PTB-DM [TB0105]

Diabetes mellitus (DM) poses a significant health risk, leading to complications in multiple organs, including the lungs. Lung function is notably reduced in DM patients, with pulmonary complications commonly observed. The comorbidity of pulmonary tuberculosis (PTB) and DM is high, with a global prevalence of about 13.73%. PTB also raises the risk of developing DM, with higher DM prevalence in PTB patients compared to those without PTB. DM increases susceptibility to PTB by disrupting innate and adaptive immune responses, while PTB impairs islet cell function through islet amyloidosis. Anti-tuberculosis drugs further affect glucose homeostasis by disrupting liver and kidney functions. Hyperglycemia in DM affects macrophage phagocytosis by altering recognition receptor expression, impairing immunity against PTB. Specifically, hyperglycemia reduces the phagocytic function of alveolar macrophages. Infection with Mycobacterium tuberculosis triggers dendritic cell maturation and migration,...

Health status and treatment outcome of TB with DM cases, Gujarat [TB0104]

The world is undergoing an epidemiological transition in disease burden, with a gradual decline in deaths from communicable diseases (CDs) and a steady rise in non-communicable diseases (NCDs). This shift has intensified competition for policy attention and resources between advocates for CDs, such as tuberculosis (TB), and those focused on NCDs, like cardiovascular diseases and diabetes mellitus (DM). The global increase in type 2 DM has emerged as a substantial challenge for TB control, as today more TB patients are living with diabetes than with concomitant human immunodeficiency virus (HIV) infection. Thus, the association between DM and TB may become the next significant challenge for global TB control. The bidirectional relationship between TB and DM is well-documented. Diabetes is an independent risk factor for TB development, while TB can also lead to impaired glucose tolerance (IGT) and new-onset diabetes. Additionally, diabetes may alter TB symptoms, radiological findings, ...

Relationship between the length of treatment for PTB and Hb levels [TB0103]

The notification rate for all tuberculosis cases in Central Java Province in 2022 was 179 per 100,000 population, an increase from 110 per 100,000 population in 2021. Semarang City continues to rank as the highest regency/city, with a Case Notification Rate (CNR) for all TB cases at 348 per 100,000 population. Kedungmundu District has the highest number of pulmonary TB cases, with a total of 186 cases, followed by Bangetayu District with 158 pulmonary TB cases. TB treatment begins with an intensive phase lasting for the first two months, potentially followed by an advanced phase. Long-term TB treatment often leads to issues with patient compliance. Noncompliance in tuberculosis treatment can have a negative impact on clinical outcomes and public health. Hematological abnormalities are common in TB patients, including leukocytosis, monocytosis, lymphocytosis, thrombocytosis, lymphopenia, and anemia. Anti-TB drugs such as isoniazid and rifampicin can cause hemolytic anemia or metabolic d...

Adults with Mtb infection and pre-DM have increased levels of IGR [TB0102]

Immunopathy associated with diabetes or pre-diabetes is characterized, in part, by chronic inflammation driven by persistent hyperglycemia, resulting in several complications. Generally, data from clinical tuberculosis (TB) studies indicate that patients with diabetes demonstrate a robust TB antigen-specific immune response. However, diabetes is paradoxically associated with worse TB clinical outcomes, including delayed culture conversion, increased risk of mortality, and higher rates of TB relapse. Although diabetes is an established risk factor for TB disease, additional information to identify individuals with diabetes and latent TB infection (LTBI) at greatest risk of progression to TB disease is urgently needed. Previous studies among children, adolescents, and adults who converted from a negative to a positive LTBI test reported that increased quantitative QuantiFERON-TB Gold (QFT) interferon-gamma (IFN-γ) values were predictive of progression to TB disease. Participants who self...

Glycemic control during TB treatment among Filipinos [TB0101]

·   High TB Incidence in the Philippines : The Philippines has one of the highest TB incidences globally (539/100,000). ·   Diabetes Prevalence : In 2020, 6.5% of Filipino adults were estimated to have diabetes mellitus (DM), as reported by the International Diabetes Federation. ·   Impact of Poor Glycemic Control : Poor long-term glycemic control, measured by HbA1c, is associated with an increased risk of TB, severe clinical presentations, and poor TB treatment outcomes. ·   Factors Affecting Glycemic Control : Individual health status, disease management practices, and the health system all influence glycemic control in DM patients. ·   Central Obesity as a Diabetes Risk Factor : Central obesity, common in Asian populations, predicts diabetes and is associated with hyperglycemia and poor glycemic control at TB treatment onset, which can negatively impact TB outcomes. ·   TB and Transient Hyperglycemia : TB-related inflammation and insulin resistance may c...

Treatment of tuberculosis

Treatment of Drug-Susceptible TB (DS-TB) For the past 50 years, DS-TB has been treated with the 'short-course chemotherapy' regimen, which includes an ‘intensive’ phase of 2 months of rifampicin, isoniazid, and pyrazinamide, followed by a ‘continuation’ phase of 4 months with rifampicin and isoniazid. This approach has been effective in curing most patients. Rifapentine, a rifamycin with a longer half-life, combined with isoniazid, pyrazinamide, and moxifloxacin, has been shown to reduce therapy duration to 4 months. In May 2022, the WHO conditionally recommended this 4-month regimen for eligible individuals aged 12 and older with pulmonary DS-TB. Treatment of Isoniazid-Resistant, Rifampicin-Susceptible TB Isoniazid resistance without concurrent rifampicin resistance is the most common form of Mycobacterium tuberculosis resistance globally, affecting an estimated 10.6% of all TB cases in 2019. In 2018, WHO recommended a regimen of 6 months of rifampicin, ethambutol, pyrazinamid...

TB control and prospects for reducing TB incidence, prevalence, and deaths globally

The technology to control TB has long existed, but it remains underutilized. Initially, the term "DOTS" (Directly Observed Treatment, Short-course) referred specifically to directly observed treatment combined with short-course chemotherapy. However, DOTS has evolved into a broader public health strategy with five principal elements: Political commitment. Case detection by sputum smear microscopy, primarily among symptomatic, self-referring patients. Standard short-course chemotherapy with supportive patient management, including DOT. A reliable system for regular drug supply. A standard recording and reporting system, including the evaluation of treatment outcomes. The MDG framework for TB control includes two measures aimed at DOTS implementation (case detection and treatment success) and three impact measures (incidence, prevalence, and deaths) relevant to all TB control methods. This second set of measures not only promotes epidemiological evaluation beyond implementation...